06:48:14 Europe / Stockholm

Share price & Turnover

Share price change and turnover during the day of this press release

Subscription

Calendar

2025-02-21 Year-end Report 2024
2024-08-09 Half year report
2024-06-13 Annual General meeting
2024-05-02 Ex-date Ordinary Dividend BONEH 0.00 EUR
2024-02-26 Year-end Report 2023
2023-10-23 Extra General Meeting 2023
2023-08-25 Half year report
2023-05-02 Ex-date Ordinary Dividend BONEH 0.00 EUR
2023-04-28 Annual General meeting
2023-02-24 Year-end Report 2022
2022-08-25 Half year report
2022-04-29 Ex-date Ordinary Dividend BONEH 0.00 EUR
2022-04-28 Annual General meeting
2022-03-17 Extra General Meeting 2022
2022-02-24 Year-end Report 2021
2021-08-25 Half year report
2021-04-29 Ex-date Ordinary Dividend BONEH 0.00 EUR
2021-04-28 Annual General meeting
2021-02-24 Year-end Report 2020
2020-08-31 Half year report
2020-04-06 Ex-date Ordinary Dividend BONEH 0.00 EUR
2020-04-05 Annual General meeting
2020-03-20 Year-end Report 2019
2019-08-30 Half year report
2019-04-08 Ex-date Ordinary Dividend BONEH 0.00 EUR
2019-04-05 Annual General meeting
2018-08-30 Half year report
2018-03-29 Annual General meeting

Description

CountryFinland
ListFirst North Finland
SectorHealth care
IndustryMedical technology
BBS-Bioactive Bone Substitutes är verksamt inom medicinteknik. Bolaget designar, utvecklar och konstruerar biologiska implantat för patienter med benfel och läkningsbesvär. Bolagets lösningar vidaresäljs under varumärket Artebone och baseras på tricalciumfosfat (TCP) och benprotein, som stimulerar benläkningsprocessen. Bolaget grundades under 2003 och har sitt huvudkontor i Oulu.
2024-01-31 17:00:00

BBS-Bioactive Bone Substitutes Plc, Company announcement, 31 January 2024 at 6.00 p.m. EET

BBS-Bioactive Bone Substitutes has resolved on a share issue without consideration to the company itself

BBS-Bioactive Bone Substitutes Plc's Board of Directors has decided on 31 January 2023 to issue 1,000,000 shares without consideration to the company itself, for potential loan conversions as well as for other possible purposes, in accordance with authorisation from the Extraordinary Shareholders' Meeting on 23 October, 2023.

After the directed share issue, the Company holds 1,000,000 treasury shares, representing approximately 4.9 percent of the total shares, after the new shares have been registered in the trade register.

For more information, please contact:

Juliusz Rakowski, CEO
+358 50 448 5132
juliusz.rakowski@bbs-artebone.fi

Certified Advisor:
Nordic Certified Adviser AB,
+46 70 551 67 29,
info@certifiedadviser.se

BBS in brief

BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi